A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a Continuous 48-hour Intravenous Infusion in Patients With Advanced Solid Malignancies
Phase 1
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Tumors
Both
Tumors
Trial Information
A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a Continuous 48-hour Intravenous Infusion in Patients With Advanced Solid Malignancies
Inclusion Criteria:
- Histological or cytological confirmation of a solid, malignant tumour
- At least one measurable or non-measurable site of disease as defined by Response
Evaluation Criteria in Solid Tumors (RECIST) criteria.
Exclusion Criteria:
- Participation in an investigational drug study within the 21 days prior to therapy or
those who have not recovered from the effects of an investigational study drug
- Recent major surgery within 4 weeks prior to entry into the study
Type of Study:
Interventional
Study Design:
Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Principal Investigator
Emerging Oncology Medical Science Director, MD
Investigator Role:
Study Director
Investigator Affiliation:
AstraZeneca
Authority:
United States: Food and Drug Administration
Study ID:
D1531C00002
NCT ID:
NCT00338182
Start Date:
May 2006
Completion Date:
January 2013
Related Keywords:
- Tumors
- Solid tumor
Name | Location |
|---|---|
| Research Site | Beverly, Massachusetts |
| Research Site | Albany, New York |
